![Sample our Engineering & Technology journals, sign in here to start your access, latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5933/TOC-Subject-Sample-2021-Engineering-Tech.jpg"})
Abstract
The advent of drug-eluting stents has revolutionized the treatment of coronary heart disease. Interventional cardiologists are increasingly treating more complex lesions in patients that would have otherwise required bypass surgery. As a result of technological advances, the second-generation thin strut TAXUS stent – the TAXUS® Liberté™ SR paclitaxel-eluting coronary stent – has now been introduced into routine clinical practice. The Liberté stent has evolved from the currently available TAXUS Express™ stent to provide enhanced lesion access in challenging anatomies as well as more uniform drug delivery. This article will provide an overview of the TAXUS Liberté stent.